suffered serious mental health side effects. In 2020, the FDA issued its most severe warning about serious mood and behavior-related changes. Plaintiffs claim that Merck failed to warn parents, patients, and doctors about the danger Singulair Lawsuit
Why are Singulair Lawsuits being Filed?
Singulair is a medication that’s used to treat severe asthma and allergies in children and adults. The U.S. Food and Drug Administration (FDA) added a boxed warning in March 2020 for serious mental side effects.
Plaintiffs now include parents of children who have suffered from psychiatric disorders following taking Singulair. They are suing Merck for: Designing a defective product, negligence, and failure to warn of the possibility of mental problems.
Merck was sued for knowing or should have known that Singulair could cause neuropsychiatric injury during treatment, and even after it stopped selling the drug.
Stephanie Hammar, for her minor son R.S.B. filed a lawsuit in September 2020 in the Eastern District Wisconsin. R.S.B. R.S.B. took Singulair between December 2010 and August 2012. The drug led to him being admitted to an inpatient mental health center. According to the lawsuit.
Hammar’s son was taken into hospital for suicidal and homicidal thoughts. His mental disorders included major depressive disorder and anxiety disorder. He also had sexual thoughts, poor coping skills, and other mental issues.
Black Box Warning Leads to Lawsuits
After Singulair was added to the drug label in March 2020, a black box warning about serious neuropsychiatric events was added by FDA. Plaintiffs started filing lawsuits immediately.
The FDA’s most severe warning is a black box warning. These warnings include important side effect information, surrounded by a thick border of black and bold letters to warn about permanent, serious, or fatal side effects.